ArticleDiabetes, obesity & metabolism2026
Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsRenal microvascular dysfunction is a central driver of diabetic kidney disease, yet the potential for rapid therapeutic reversal remains obscure. We investigated the effect of short-term liraglutide on early changes in the renal microcirculation post-induction of diabetes. MATERIALS AND
methodsType 2 diabetes mellitus (T2DM) was induced in BALB/c mice via high-fat diet and streptozotocin. Following induction, mice received insulin or liraglutide treatments for 1 or 2 weeks. Renal microhemodynamics was analysed using laser Doppler flowmetry and wavelet analysis. Histopathological evaluations via Masson trichrome and haematoxylin-eosin staining assessed fibrosis and microvascular integrity. Primary renal microvascular endothelial cells (RMECs) were isolated to evaluate angiogenic and migratory behaviours. Metabolomics analyses were performed to link metabolic changes with microcirculatory alterations.
resultsT2DM induced significant impairments in renal microcirculation, characterised by dysregulated microhemodynamics, disturbed oxygen saturation, altered haemoglobin distribution and compromised blood perfusion. These functional defects were accompanied by elevated creatinine, reduced cystatin C and impaired angiogenic and migratory capacity of RMECs under glucotoxicity. Both insulin and liraglutide treatments ameliorated renal microcirculatory oxygen profiles and improved renal function biomarkers. Histological data revealed decreased fibrosis and enhanced microvascular architecture post-treatment. Metabolomic profiling revealed that liraglutide preferentially restored depleted amino acid levels associated with microvascular function, a change associated with the normalisation of metabolic profiles potentially involving peptide transport pathways.
conclusionsOur findings demonstrate that short-term liraglutide restores renal microcirculatory homeostasis in the post-induction phase, mitigating microvascular dysfunction and preserving kidney structure, highlighting the potential therapeutic value in preventing the progression of diabetic renal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.